Literature DB >> 16049166

Heterogeneity and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) subtypes expressed on retinal afferents of the superior colliculus and lateral geniculate nucleus: identification of a new native nAChR subtype alpha3beta2(alpha5 or beta3) enriched in retinocollicular afferents.

Cecilia Gotti1, Milena Moretti, Alessio Zanardi, Annalisa Gaimarri, Nicolas Champtiaux, Jean-Pierre Changeux, Paul Whiteaker, Michael J Marks, Francesco Clementi, Michele Zoli.   

Abstract

The activation of neuronal nicotinic acetylcholine receptors (nAChRs) has been implicated in the activity-dependent development and plasticity of retina and the refinement of retinal projections. Pharmacological and functional studies have also indicated that different presynaptic nAChRs can have a modulatory function in retinotectal synapses. We biochemically and pharmacologically identified the multiple nAChR subtypes expressed on retinal afferents of the superior colliculus (SC) and lateral geniculate nucleus (LGN). We found that the alpha6beta2(*) and alpha4(nonalpha6)beta2(*) nAChRs are the major receptor populations expressed in both SC and LGN. In addition, the LGN contains two minor populations of alpha2alpha6beta2(*) and alpha3beta2(*) subtypes, whereas the SC contains a relatively large population of a new native subtype, the alpha3beta2(alpha5/beta3) nAChR. This subtype binds the alpha-conotoxin MII with an affinity 50 times lower than that of the native alpha6beta2(*) subtype. Studies of tissues obtained from eye-enucleated animals allowed the identification of nAChRs expressed by retinal afferents: in SC alpha6beta2(*), alpha4alpha6beta2(*), and alpha3beta2(*) (approximately 45, 35, and 20%, respectively), in LGN, alpha4alpha6beta2(*), alpha6beta2(*), alpha4beta2(*), alpha2alpha6beta2(*), and alpha3beta2(*) (approximately 40, 30, 20, 5, and 5%, respectively). In both regions, more than 50% of nAChRs were not expressed by retinal afferents and belonged to the alpha4beta2(*) (90%) or alpha4alpha5beta2(*) (10%) subtypes. Moreover, studies of the SC tissues obtained from wild-type and alpha4, alpha6, and beta3 knockout mice confirmed and extended the data obtained in rat tissue and allowed a comprehensive dissection of the composition of nAChR subtypes present in this retinorecipient area.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049166     DOI: 10.1124/mol.105.015925

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  25 in total

1.  Modulation of recombinant, α2*, α3* or α4*-nicotinic acetylcholine receptor (nAChR) function by nAChR β3 subunits.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

Review 2.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

Review 3.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

Review 4.  Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors.

Authors:  Sharon R Letchworth; Paul Whiteaker
Journal:  Biochem Pharmacol       Date:  2011-06-28       Impact factor: 5.858

5.  Morphine dependence and withdrawal induced changes in cholinergic signaling.

Authors:  Nichole M Neugebauer; Emily B Einstein; Maria B Lopez; Tristan D McClure-Begley; Yann S Mineur; Marina R Picciotto
Journal:  Pharmacol Biochem Behav       Date:  2013-05-04       Impact factor: 3.533

6.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

7.  In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.

Authors:  F Ivy Carroll; Hernán A Navarro; S Wayne Mascarella; Ana H Castro; Charles W Luetje; Charles R Wageman; Michael J Marks; Asti Jackson; M Imad Damaj
Journal:  ACS Chem Neurosci       Date:  2015-04-30       Impact factor: 4.418

8.  Stable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonists.

Authors:  Anna Maria Capelli; Laura Castelletti; Yu Hua Chen; Harjeet Van der Keyl; Luca Pucci; Beatrice Oliosi; Cristian Salvagno; Barbara Bertani; Cecilia Gotti; Andrew Powell; Manolo Mugnaini
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

9.  Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.

Authors:  Y S Mineur; D H Brunzell; S R Grady; J M Lindstrom; J M McIntosh; M J Marks; S L King; M R Picciotto
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

10.  Effects of glaucoma on Chrna6 expression in the retina.

Authors:  Gustavo C Munguba; Eldon E Geisert; Robert W Williams; Mary L Tapia; Daisy K Lam; Sanjoy K Bhattacharya; Richard K Lee
Journal:  Curr Eye Res       Date:  2012-09-24       Impact factor: 2.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.